Interstitial nephritis with pembrolizumab: A case report and review
- 12 October 2020
- journal article
- case report
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 27 (4) , 1046-1051
Abstract
Introduction: Pembrolizumab is a monoclonal antibody approved for adult patients with advanced non–small-cell lung cancer (NSCLC). Although immune related adverse events are considered to be well tolerated, complications may occur and discontinuation of the treatment could be required. Case report: A 62-year old patient diagnosed with advanced non-small cell lung cancer experienced a decline in the renal function after seven cycles with pembrolizumab. Management & outcome: After ruling out other common causes of interstitial nephritis, pembrolizumab was attributed as a cause of interstitial nephritis. At first, toxicity was managed with corticosteroids and closely monitoring the patient, but finally pembrolizumab had to be discontinued due to the kidney function did not recover. Discussion: Renal and urinary disorders were reported in <3% of patients treated with pembrolizumab, being interstitial nephritis the most reported toxicity. The kidney damage can be a complication to consider in patients receiving pembrolizumab. Early identification of an increase in serum creatinine levels may help with prevention by establishing an effective treatment, although it may not mean a total recovery of kidney function.Keywords
This publication has 23 references indexed in Scilit:
- Acute Kidney Injury after Pembrolizumab-Induced Adrenalitis and Adrenal InsufficiencyCase Reports in Nephrology and Dialysis, 2018
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Adverse kidney effects of epidermal growth factor receptor inhibitorsNephrology Dialysis Transplantation, 2017
- Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitorJournal for ImmunoTherapy of Cancer, 2017
- Acute interstitial nephritis related to immune checkpoint inhibitorsBritish Journal of Cancer, 2016
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsKidney International, 2016
- Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesotheliomaBMC Cancer, 2016
- Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer PatientsAmerican Journal of Kidney Diseases, 2016
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981